Enanta Pharmaceuticals Inc (ENTA): Revenue
$65.32M
Year ended 2025-09-30
$65.26M
Trailing 12 months to 2026-06-30
-8.8%
3-year compound annual growth
-11.8%
5-year compound annual growth
-8.6%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $65.32M | -3.4% | 2025-11-19, From 2024-10-01 |
| 2024-09-30 | $67.64M | -14.6% | 2025-11-19, From 2023-10-01 |
| 2023-09-30 | $79.20M | -8.1% | 2025-11-19, From 2022-10-01 |
| 2022-09-30 | $86.16M | -11.2% | 2024-11-27, From 2021-10-01 |
| 2021-09-30 | $97.07M | -20.7% | 2023-11-22, From 2020-10-01 |
| 2020-09-30 | $122.47M | -40.3% | 2022-11-23, From 2019-10-01 |
| 2019-09-30 | $205.20M | -0.7% | 2021-11-24, From 2018-10-01 |
| 2018-09-30 | $206.62M | +101.0% | 2020-11-25, From 2017-10-01 |
| 2017-09-30 | $102.81M | +16.5% | 2019-11-27, From 2016-10-01 |
| 2016-09-30 | $88.27M | -45.1% | 2018-11-29, From 2015-10-01 |
| 2015-09-30 | $160.88M | +237.0% | 2017-12-11, From 2014-10-01 |
| 2014-09-30 | $47.74M | +48.9% | 2016-12-09, From 2013-10-01 |
| 2013-09-30 | $32.05M | -23.1% | 2015-12-11, From 2012-10-01 |
| 2012-09-30 | $41.71M | -0.4% | 2014-12-11, From 2011-10-01 |
| 2011-09-30 | $41.88M | n/a | 2013-12-18, From 2010-10-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $65.32M | -3.4% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $66.80M | +39.2% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $63.26M | +9.7% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $67.48M | +25.2% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $62.90M | +699.0% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $62.38M | +48.3% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $69.26M | -31.8% |
| Journey Medical Corp (DERM) | 2025-12-31 | $61.24M | +11.1% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $70.85M | n/m |
Compare ENTA, SPRO, FBIO, KURA side by side · Screen every company in Pharmaceutical Preparations ↗